Straits Times Index
3,426.47 -3.98 (-0.12%) S&P 500
5,459.10 +59.88 (+1.11%) Dow
40,589.34 +654.24 (+1.64%) Nasdaq
17,357.88 +176.18 (+1.03%) Bitcoin USD
68,132.88 -594.22 (-0.86%) CMC Crypto 200
1,374.30 +43.69 (+3.28%)
Terumo Corporation (TUO0.MU)
| Previous close | 15.90 |
| Open | 15.90 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 15.90 - 15.90 |
| 52-week range | 12.10 - 32.80 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 24.026B |
| Beta (5Y monthly) | 0.47 |
| PE ratio (TTM) | 36.98 |
| EPS (TTM) | 0.43 |
| Earnings date | 08 Aug 2024 |
| Forward dividend & yield | 0.13 (0.83%) |
| Ex-dividend date | 27 Mar 2024 |
| 1y target est | N/A |
ZacksTerumo (TRUMY) Unit Reveals WEB 17 Device Effective in Aneurysms
Terumo's (TRUMY) subsidiary MicroVention's WEB 17 device, used in treating intracranial aneurysms, demonstrates high safety and effectiveness in the CLEVER study.
Business WireMicroVention Announces Release of CLinical EValuation of WEB™ 17 Device in Intracranial Aneurysms (CLEVER): One Year Effectiveness Results for Ruptured and Unruptured Aneurysms
COLORADO SPRINGS, Colo. & ALISO VIEJO, Calif., July 23, 2024--MicroVention, Inc., a global neurovascular company and wholly owned subsidiary of Terumo Corporation, today announced the recently published results of the CLinical EValuation of WEB 17 Device in Intracranial Aneurysms (CLEVER): One Year Effectiveness Results for Ruptured and Unruptured Aneurysms. The CLEVER study was a multicenter, prospective study evaluating the WEB 17 system in ruptured and unruptured aneurysms to understand the s
ZacksTerumo (TRUMY) Unit's SOFAST Study Shows Positive Results
Terumo (TRUMY) subsidiary Microvention's SOFAST study validates the SOFIA Flow Plus Aspiration Catheter's speed, efficacy and safety in stroke thrombectomy.
